Literature DB >> 9987624

The favorable effect of topical betaxolol and timolol on glaucomatous visual fields: a 2-year follow-up study.

E Vainio-Jylhä1, M L Vuori.   

Abstract

BACKGROUND: It has been suggested that beta-adrenergic antagonists might have mechanisms of action other than ocular hypotensive effects affecting the visual function in glaucoma patients and that betaxolol might protect the visual field better than others. A randomized, double-blind study was conducted to compare the effects of betaxolol and timolol on visual fields of glaucoma patients.
METHODS: Sixty-four glaucoma patients were treated with either 0.5% betaxolol or 0.25% timolol eyedrops twice daily. The Octopus visual field performance was followed up for 2 years and analyzed to find diffuse and localized changes. We analyzed the change in the mean sensitivity (MS) and performed a cluster analysis and clinical assessment of the visual fields in both treatment groups.
RESULTS: The mean sensitivity (MS) improved significantly and equally in both treatment groups. There was a tendency towards more improved clusters in the betaxolol group than in the timolol group and more worsened cluster in the timolol group than in the betaxolol group, but the difference was not statistically significant. The clinical assessment also showed no statistically significant difference between the two groups.
CONCLUSION: In the present study both betaxolol and timolol had a favorable effect on the visual fields of glaucoma patients. There was no statistically significant difference between betaxolol- and timolol-treated patients either in the change in mean retinal sensitivity or in the change in localized scotomatous areas.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9987624     DOI: 10.1007/s004170050202

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  5 in total

1.  The effect of topical glaucoma medications evaluated by perimetry.

Authors:  J-C Lin; F Samuel; L J Katz; G L Spaeth; J Hoop; L B Cantor
Journal:  Br J Ophthalmol       Date:  2003-06       Impact factor: 4.638

2.  Acquired color vision loss and a possible mechanism of ganglion cell death in glaucoma.

Authors:  T M Nork
Journal:  Trans Am Ophthalmol Soc       Date:  2000

Review 3.  Pharmacological neuroprotection for glaucoma.

Authors:  Glyn Chidlow; John P M Wood; Robert J Casson
Journal:  Drugs       Date:  2007       Impact factor: 9.546

Review 4.  Medical interventions for primary open angle glaucoma and ocular hypertension.

Authors:  C Vass; C Hirn; T Sycha; O Findl; P Bauer; L Schmetterer
Journal:  Cochrane Database Syst Rev       Date:  2007-10-17

Review 5.  Neuroprotection in glaucoma.

Authors:  Sushil K Vasudevan; Viney Gupta; Jonathan G Crowston
Journal:  Indian J Ophthalmol       Date:  2011-01       Impact factor: 1.848

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.